Search alternatives:
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
non decrease » point decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
241
-
242
FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells.
Published 2019“…<p>(A) Following 24 hours of treatment with FTY720, the viability of HuH6 cells measured using the alamarBlue cell viability assay was significantly decreased (LD<sub>50</sub> = 8.4 μM, p ≤ 0.05). …”
-
243
-
244
-
245
-
246
Predicting pattern diversity decreases as a function of and .
Published 2025“…(a) and (b): Average negative predictive value for and , respectively for and . …”
-
247
-
248
-
249
-
250
Apparent Non-Newtonian Behavior of Ionic Liquids
Published 2020“…Depending on the liquid and the rheological conditions, both viscosity increase and decrease have been reported. So far, these variations have been interpreted as a signature of a non-Newtonian behavior. …”
-
251
-
252
Depleted antibody secreting cells did not result in decreased donor specific antibody in non-sensitized animals.
Published 2022“…Data analyzed using ANOVA. (A) T (CD3<sup>+</sup>) and (B) B (CD45R<sup>+</sup>) cell flow crossmatch was performed in non-sensitized animals. …”
-
253
-
254
-
255
-
256
-
257
-
258
-
259
-
260
Image2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF
Published 2021“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”